APOB and hypertriglyceridemia: This discordance is significant in statin users with low LDL-C but elevated ApoB or non-HDL-C [82] and also in individuals with diabetes, obesity, hypertriglyceridemia, or metabolic syndrome—where classic LDL-C underestimates risk [83].